Aspar Pharmaceuticals
Katargam, Surat, Gujarat
GST No. 24AAZFA8919K1ZO
Send SMS
Send E-mail
Aspar® Pharmaceuticals is a leading supplier, Exporter, and trader of Anti Diabetic Products. Our Product range includes a wide range of Anti Diabetic Products.
We offerJanumet Tablets, Oxra Tablets, Forxiga Tablets, Onglyza Tablets, Invokana Tablets, and many more products.
We are manufacture and export of our brand. We also offer private labeling, Contract manufacturing service.
| Minimum Order Quantity | 1 Pack |
| Composition | canagliflozin |
| Packaging Size | box |
| Packaging Type | 10 tablets |
| Form | Tablets |
| Brand | invokana / sulisent / motivyst |
| Dose/Strength | 100 mg |
| Dosage Form | Tablets |
| Expiry Date | 24 month |
| Manufacturer | AstraZeneca LTD |
| Brand | Onglyza |
| Treatment | Doctor will Administrate |
| Usage/Application | Type 2 Diabetes. |
| Composition | Saxagliptin (5mg) |
| Prescription/Non prescription | Non prescription |
| Packaging Size | 2 x 14 tablets |
| Packaging Type | box packing |
| Dose/Strength | 2.5 mg / 5mg |
| Dosage Form | Tablets |
| Expiry Date | 24 month |
| Manufactured By | AstraZeneca |
Our reputed entity is engaged in Onglyza Tablet.
BRAND : Onglyza 2.5 / Onglyza 5
COMPOSITION : Saxagliptin (2.5mg) / Saxagliptin (5mg)
COMPANY : AstraZeneca
PACK : 2 x 14 Tablets
USES OF ONGLYZA TABLET
Onglyza 2.5mg / 5 mg Tablet is used in the treatment of type 2 diabetes. It is used in addition to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
HOW TO USE ONGLYZA TABLET
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Onglyza 2.5mg / 5 mg Tablet may be taken with or without food, but it is better to take it at a fixed time.
HOW ONGLYZA TABLET WORKS
Onglyza 2.5mg / 5 mg Tablet is an anti-diabetic medication. It works by increasing the release of insulin from the pancreas and decreasing the hormones that raise blood sugar levels. This reduces the fasting and postmeal sugar levels.
| Minimum Order Quantity | 1 Pack |
| Pack size | 30 Tabs |
| Brand | Jardiance |
| Manufacturer | Boehringer Ingelheim |
| Composition | Empagliflozin 25mg |
| Prescription/Non prescription | Prescription |
| Product Type | API |
| Packaging Size | 30 Tabs |
| Packaging Type | Bottle |
| Form | Tablet |
Aspar® Pharmaceuticals is a leading manufacturer and exporter of
Jardiance 250mg Tablet ( Empagliflozin 25mg )
in different strength and packing. Our manufacturing facility is certified with WHO-GMP.
Composition:
Jardiance 250mg Tablet ( Empagliflozin 25mg )
Brand Name: Jardiance Tablet
Active Ingredients (Generic Name): Empagliflozin 25mg
Company name: Boehringer Ingelheim
Strength: 25 mg
Pack Type: Bottle
Pack Size: 30 Tabs in 1 Packet
Indication:
Jardiance 250mg Tablet ( Empagliflozin 25mg )
Jardianceis used to Type 2 Diabetes Mellitus.
Uses:-
Jardiance 250mg Tablet ( Empagliflozin 25mg )
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Jardiance 25 mg Tablet may be taken with or without food, but it is better to take it at a fixed time.
How it works:-
Jardiance 250mg Tablet ( Empagliflozin 25mg )
Jardiance 25 mg Tablet is an antidiabetic medication. It works by removing excess sugar from your body through urine.
Available other Brand :
Gibtulio 25mg.
We are manufacture and export of our brand. We also offer private labeling, Contract manufacturing service.
| Minimum Order Quantity | 1 Pack |
| Strength | 100mg or more |
| Packaging Size | 16 Tablets in 1 Strip |
| Brand | All Brands |
| Composition | Trelagliptin |
| Treatment | Type 2 Diabetes |
| Prescription/Non prescription | Prescription |
| Form | Tablet |
| Also Gives | Third Party Manufacturing |
| Shelf life | 24 months |
Trelagliptin (trade name Zafatek) is a pharmaceutical drug used for the treatment of type 2 diabetes (diabetes mellitus).
Indications, It is a highly selective dipeptidyl peptidase-4 inhibitor that is typically used as an add on treatment when the first line treatment of metformin is not achieving the expected glycemic goals; though it has been approved for use as a first line treatment when metformin cannot be used.
